Adolescent development and SLE

被引:15
作者
Beresford, MW
Davidson, JE [1 ]
机构
[1] Royal Hosp Sick Children, Dept Rheumatol, Glasgow G3 8SJ, Lanark, Scotland
[2] Royal Liverpool Childrens Hosp, Dept Rheumatol, Liverpool L12 2AP, Merseyside, England
来源
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY | 2006年 / 20卷 / 02期
关键词
systemic lupus erythematosus; adolescence; disease activity; outcome;
D O I
10.1016/j.berh.2005.11.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Adolescence is a time of profound biological and psychosocial change. The management of a complex chronic condition such as systemic lupus erythematosus (SLE) during this period is a challenging but rewarding task for the clinician. Early diagnosis and optimal disease control is essential in order to facilitate normal adolescent development and minimize long-term disease sequelae. Current treatment regimens are associated with significant toxicity in young people, and there is a need for new, less toxic regimens. There are currently no controlled therapeutic studies in adolescents with SLE. Those involved in the care of these young people must ensure that they have appropriate access to specialist medical services while ensuring that their specific needs as adolescents in the health-care system are addressed.
引用
收藏
页码:353 / 368
页数:16
相关论文
共 75 条
[1]  
Beresford M. W., 2005, Lupus, V14, P152, DOI 10.1191/0961203305lu2073oa
[2]   New insights into the pathogenesis of systemic lupus erythematosus (SLE): the role of apoptosis [J].
Bijl, M ;
Limburg, PC ;
Kallenberg, CGM .
NETHERLANDS JOURNAL OF MEDICINE, 2001, 59 (02) :66-75
[3]   Health-related quality of life in children with rheumatic diseases [J].
Brunner, HI ;
Giannini, EH .
CURRENT OPINION IN RHEUMATOLOGY, 2003, 15 (05) :602-612
[4]   Lupus headaches in childhood-onset systemic lupus erythematosus: relationship to disease activity as measured by the systemic lupus erythematosus disease activity index (SLEDAI) and disease damage [J].
Brunner, HI ;
Jones, OY ;
Lovell, DJ ;
Johnson, AM ;
Alexander, P ;
Klein-Gitelman, MS .
LUPUS, 2003, 12 (08) :600-606
[5]  
Brunner HI, 2003, J RHEUMATOL, V30, P292
[6]   Risk factors for damage in childhood-onset systemic lupus erythematosus - Cumulative disease activity and medication use predict disease damage [J].
Brunner, HI ;
Silverman, ED ;
To, T ;
Bombardier, C ;
Feldman, BM .
ARTHRITIS AND RHEUMATISM, 2002, 46 (02) :436-444
[7]   Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus [J].
Bultink, IEM ;
Lems, WF ;
Kostense, PJ ;
Dijkmans, BAC ;
Voskuyl, AE .
ARTHRITIS AND RHEUMATISM, 2005, 52 (07) :2044-2050
[8]  
Buratti S, 2001, J RHEUMATOL, V28, P2103
[9]   Antinuclear antibodies are common in an infectious environment but do not predict systemic lupus erythematosus [J].
Cainelli, F ;
Betterle, C ;
Vento, S .
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (12) :1707-1708
[10]   Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis [J].
Chan, TM ;
Li, FK ;
Tang, CSO ;
Wong, RWS ;
Fang, GX ;
Ji, YL ;
Lau, CS ;
Wong, AKM ;
Tong, MKL ;
Chan, KW ;
Lai, KN .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (16) :1156-1162